The European Commission gives the go-ahead to commercialize the Novavax vaccine in Europe




Agencies | Eitb Media

The American Novavax will be able to deliver to the EU up to 100 million doses against its ‘Nuvaxovid’ vaccine in the first quarter of 2022. According to studies carried out, the vaccine has been shown to be 90% effective in reducing symptomatic cases.

The European Comission has granted a conditional marketing authorization (ACC) for the covid-19 vaccine Nuvaxovid, developed by the American laboratory Novavax, which makes it the fifth “safe and effective” vaccine against covid-19 authorized in the EU.

“At this time, the variant omicron it is spreading rapidly, so we need to step up vaccination and booster doses. For this reason, I am especially pleased to announce today the authorization of the Novavax vaccine “, said the President of the European Commission, Ursula von der Leyen.

The Commission signed the contract with Novavax on August 4, 2021. Thanks to the conditional marketing authorization, Novavax will be able to deliver to the EU up to 100 million doses against covid-19 in the first quarter of 2022. The contract allows Member States acquire an additional 100 million doses over the course of 2022 and 2023.

The first doses are expected to arrive in the first months of 2022, and Member States have requested around 27 million doses for that first quarter. These will be added to the 2.4 billion doses of the vaccine from BioNTech-Pfizer, the 460 million from Moderna, the 400 million from AstraZeneca and the 400 million from Janssen.

“I hope this authorization encourages all people who have not yet done so to get vaccinated or request the booster dose. It is time to do it “, has added.

See also  My surprising hand in signing Sauzee and why Hibs need Frenchman's spirit against Hearts - Tam McManus

This authorization follows a Favorable scientific recommendation based on a thorough evaluation of the safety, efficacy and quality of the vaccine by the European Medicines Agency (EMA) and is endorsed by the Member States.

“This is our first protein vaccine, which has shown promising results against covid-19,” said Stella Kyriakides, Commissioner for Health and Food Safety, who stressed that the importance of “getting vaccinated, vaccinated and vaccinated”

“If we want to stop the wave of infections and counteract the appearance and spread of new variants, vaccination and the administration of booster doses to increase protection against covid-19 are now more important than ever,” he concluded.

90% efficient

The results of the two main clinical trials revealed that Nuvaxovid It was effective in preventing covid-19 in people 18 years of age and older. More than 45,000 people in total participated in the studies.

In the first study, about two-thirds of the participants received the vaccine and the rest received a placebo injection (dummy); In the other study, the participants were evenly divided among Nuvaxovid and placebo. The participants did not know if they had received Nuvaxovid or placebo.

Taken together, the results of the two studies show an efficacy of the vaccine Nuvaxovid of about 90 percent. The parent strain of SARS-CoV-2 and some worrisome variants, such as alfa and the beta, they were the most common viral strains circulating when the studies were conducted. However, there are currently limited data on the efficacy of Nuvaxovid against other variants of interest, including omicron The delta.


Related Posts

George Holan

George Holan is chief editor at Plainsmen Post and has articles published in many notable publications in the last decade.

Leave a Reply

Your email address will not be published.